A fast and reliable LC-MS/MS method for simultaneous quantitation of fluoxetine and mirtazapine in human plasma

被引:7
作者
Alegete, Pallavi [1 ,2 ]
Kancherla, Prasad [3 ]
Albaseer, Saeed S. [4 ]
Boodida, Sathyanarayana [1 ]
机构
[1] JNTU Coll Engn Jagityal, Dept Chem, Karimnagar, Telangana State, India
[2] Spectrum Pharma Res Solut, Hyderabad, Telangana State, India
[3] Jawaharlal Nehru Technol Univ Hyderabad, Inst Sci & Technol, Ctr Chem Sci & Technol, Kukatpally, Telangana State, India
[4] Thamar Univ, Fac Educ, Dept Chem, Thamar, Yemen
关键词
DEPRESSION; OLANZAPINE; DISORDER; MS;
D O I
10.1039/c4ay01057d
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid and sensitive ultra-performance liquid chromatographic/tandemmass spectrometric assay (LC-MS/MS) was developed to simultaneously quantify fluoxetine and mirtazapine in human plasma using fluoxetine-D5 and olanzapine as internal standards (IS), respectively. The analytes and the internal standards (IS) were extracted from 400 mu L aliquots of human plasma through liquid-liquid extraction. Chromatographic separation was achieved in a run time of 2.0 min on the X-terra RP8 (50 x 4.6 mm, 5 mm particle size) column. The isocratic mobile phase consisting of a mixture of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow-rate of 0.50 mL min(-1) was found to be optimum. Quantitation of analytes was performed by electrospray ionization tandem mass spectrometry, operating in positive-ion and multiple reaction monitoring (MRM) acquisition mode. The protonated precursors to product ion transitions monitored for fluoxetine, mirtazapine, fluoxetine-D5 and olanzapine were at m/z 310.20 -> 148.17, 266.35 -> 195.31, 315.20 -> 153.17 and 313.19 -> 256.12, respectively. The method was validated over the concentration range of 0.050-50.037 ng mL(-1) for fluoxetine and 0.100-100 000 ng mL(-1) for mirtazapine in human plasma. The method has shown high reproducibility with intra-batch and inter-batch precision (CV%) less than 10.16% across four quality control levels for both the analytes. The assay was linear over the concentration range of 0.050-50.037 ng mL(-1) for fluoxetine (r(2) = 0.9988) and 0.100-100 000 ng mL(-1) for mirtazapine (r(2) = 0.9975). The method is suitable for measuring accurate concentration of the two analytes in bioequivalence study and therapeutic drug monitoring following combined administration.
引用
收藏
页码:7407 / 7414
页数:8
相关论文
共 21 条
  • [1] Altamura A. C., 1991, USE FLUOXETINE CLIN, V183, P53
  • [2] ALTAMURA AC, 1989, INT J CLIN PHARM RES, V9, P391
  • [3] [Anonymous], 2001, GUID IND BIOAN METH
  • [4] Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
    Baldwin, DS
    Anderson, IM
    Nutt, DJ
    Bandelow, B
    Bond, A
    Davidson, JRT
    den Boer, JA
    Fineberg, NA
    Knapp, M
    Scott, J
    Wittchen, HU
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) : 567 - 596
  • [5] FLUOXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS
    BENFIELD, P
    HEEL, RC
    LEWIS, SP
    [J]. DRUGS, 1986, 32 (06) : 481 - 508
  • [6] Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study
    Blier, Pierre
    Ward, Herbert E.
    Tremblay, Philippe
    Laberge, Louise
    Hebert, Chantal
    Bergeron, Richard
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (03) : 281 - 288
  • [7] Chorilli M, 2011, AM J ANAL CHEM, V2, P650
  • [8] Stir bar sorptive extraction-LC-MS for the analysis of fluoxetine in plasma
    Fernandes, C.
    Jiayu, P.
    Sandra, P.
    Lancas, F. M.
    [J]. CHROMATOGRAPHIA, 2006, 64 (9-10) : 517 - 521
  • [9] A systematic review of the serotonergic effects of Mirtazapine in humans: implications for its dual action status
    Gillman, PK
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2006, 21 (02) : 117 - 125
  • [10] Mirtazapine in major depression with comorbid generalized anxiety disorder
    Goodnick, PJ
    Puig, A
    DeVane, CL
    Freund, BV
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) : 446 - 448